Innovation translates into antidepressant effectiveness.
Unipolar depression is a major cause of disability in developed societies. There is significant unmet need because existing treatments are neither as effective nor as free of adverse effects as we would hope. Agomelatine is a new antidepressant with a novel profile of pharmacological action. Its efficacy in major depression has been reported in short-term placebo-controlled trials and in direct head-to-head comparison with existing products. The pooling of data from the agomelatine short-term...Expand abstract
- Publisher copy:
- Pubs id:
- Local pid:
- Deposit date:
- Copyright date:
If you are the owner of this record, you can report an update to it here: Report update to this record